Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|July 16, 2015
[Strychnine poisoning: uncommon, but does still happen]Inge R F van Berlo-van de Laar, Maurits E L Arbouw, Carmen M A Bles
European Journal of Clinical Pharmacology|January 4, 2007
Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patientsMaurits E L Arbouw, Kris L L Movig, Cees Neef, et al.
Pharmacogenomics|February 9, 2007
Pharmacogenetics of antiparkinsonian drug treatment: a systematic reviewMaurits E L Arbouw, Jeroen P P van Vugt, Toine C G Egberts, et al.
European Journal of Clinical Pharmacology|July 23, 2011
Dopamine agonists and ischemic complications in Parkinson's disease: a nested case-control studyMaurits E L Arbouw, Kris L L Movig, Henk-Jan Guchelaar, et al.
Biomedical Chromatography : BMC|June 10, 2026
An Optimized Sample Pretreatment Method Followed by a Validated LC-MS/MS Method for Quantifying 6-TG and 6-MMP Concentrations in Red Blood Cells for Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Using ThiopurinesInge R F van Berlo-van de Laar, Willem M J Basten, Maurits E L Arbouw, et al.
Biomedical Chromatography : BMC|April 8, 2024
A rapid and sensitive LC-MS/MS method for quantifying oxycodone, noroxycodone, oxymorphone and noroxymorphone in human plasma to support pharmacokinetic drug interaction studies of oxycodoneLotte M G Hulskotte, Inge Wilbrink-Pijffers, Maurits E L Arbouw, et al.
European Journal of Clinical Pharmacology|July 16, 2008
Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: clinical practice versus clinical trialsMaurits E L Arbouw, Kris L L Movig, Henk-Jan Guchelaar, et al.
British Journal of Clinical Pharmacology|March 10, 2020
Optimising the dose of clonidine to achieve sedation in intensive care unit patients with population pharmacokineticsMichael E Cloesmeijer, Huub L A van den Oever, Ron A A Mathôt, et al.
European Journal of Clinical Pharmacology|August 12, 2009
Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's diseaseMaurits E L Arbouw, Kris L L Movig, Toine C G Egberts, et al.
Pageof 1